<DOC>
	<DOC>NCT02015312</DOC>
	<brief_summary>Efficacy and safety of epigallocatechin-3-gallate (EGCG) in patients with cardiac amyloid light-chain (AL) amyloidosis. Evaluation of clinical efficacy of EGCG intake using a pretest posttest comparison of left ventricular amyloid mass (g/m2) measured by cardiac MRI.</brief_summary>
	<brief_title>A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Biopsy proven systemic AL amyloidosis. Cardiac involvement with septum thickness more than 12 mm (without other causes as published by Gertz et al., hypertension or other potential causes of left ventricular hypertrophy) Previously treated with chemotherapy, induced at least a very good partial remission of the underlying monoclonal plasma cell or B cell disorder. GPT and GOT less than 3times ULN. Life expectancy more than 12 month. Ability of subject to understand character and individual consequences of the clinical trail. Written informed consent. For women with childbearing potential and men, adequate contraception. Age less than 18 years. Concomitant multiple myeloma stage 2 and 3 (Salmon and Durie) Concurrent chemotherapy necessary Time to last chemotherapy more than 6 months. Chronic liver disease, Bilirubin over 1,5 mg/dl Not able to visit Amyloidosis Clinic in Heidelberg every 3 months. History of hypersensitivity to the investigational product or to any substance with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product. Participation in other clinical trials or observation period of competing trials, respectively. Pregnant or nursing women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Amyloidosis</keyword>
</DOC>